Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $70,047 | $56,587 |
| General and administrative | 17,290 | 14,796 |
| Total operating expenses | 87,337 | 71,383 |
| Loss from operations | (87,337) | (71,383) |
| Interest income (expense), net | 4,380 | 3,160 |
| Other income (expense), net | (1) | (20) |
| Net loss and comprehensive loss | (82,958) | (68,243) |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s R&D?
- Eikon Therapeutics, Inc. (EIKN) reported R&D of $70.05M in Q1 2026.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Eikon Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude